Fig. 6

Effect of combinatorial treatment of parental FGFR3 fusion harboring bladder cell lines with (A, C) erdafitinib and AZD8931, or (B, D) TAS-120 and AZD8931 on cell viability. A, B Parental SW780 and (C, D) RT4 cells were treated with a range of concentrations of BGJ398 or AZD8931 alone or in combination for 72 h and cell viability determined using Cell-Titer Glo assays. Plots shown are the BLISS synergy analysis from a representative experiment, which shows synergistic growth inhibition across a range of concentrations